Both in Pharmaceuticals
MacroGenics vs Cue Biopharma
Over the past year MGNX returned +45.3% and CUE returned −12.1%; their daily moves had a correlation of -0.01.
MGNX +45.3% CUE −12.1%Growth of $1, one year, split-adjusted
| Metric | MGNX | CUE |
|---|---|---|
| Price | $2.30 | $18.92 |
| Market cap | $146.2M | $137.4M |
| Today | −1.50% | −9.30% |
| 1 month | −37.0% | −18.2% |
| 6 months | −23.8% | −44.3% |
| Year to date | +42.5% | +106.5% |
| 1 year | +45.3% | −12.1% |
| Revenue growth (YoY) | +378.0% | +166.7% |
| Gross margin | 100.0% | 100.0% |
| Net margin | 59.4% | −1943.2% |
| P/E (TTM) | — | — |
| Price / sales | 0.9× | 3.7× |
| Net cash | $173.3M | $16.4M |
| Dividend yield | — | — |
| Volatility (60d) | 113.6% | 138.7% |
| Short % of float | 8.2% | 12.2% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).